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Abstract The in vitro antifungal potency of six series of 4-
arylthiosemicarbazides was evaluated. Two isoquinoline
derivatives with an ortho-methoxy or ortho-methyl group
at the phenyl ring were the most potent antifungal
agents. Molecular modeling studies and docking of all
4-arylthiosemicarbazides into the active sites of sterol 14α-
demethylase (CYP51), topoisomerase II (topo II), L-glutamine:
D-fructose-6-phosphate amidotransferase (GlcN-6-P), secreted
aspartic proteinase (SAP), N-myristoyltransferase (NMT), and
UDP-N-acetylmuramoyl-L-alanine:D-glutamate ligase (MurD)
indicated the importance of both structural and electronic factors
in ligand recognition and thus for the antifungal effectiveness of
4-arylthiosemicarbazides. A possible antifungal target was
identified (NMT) and isoquinoline-thiosemicarbazides
showed more favorable affinity than the native ligand.
Keywords Thiosemicarbazide derivative . Antifungal
activity . Cytotoxicity . Structure-activity relationship .
Molecular docking
Introduction
Invasive fungal infections (IFIs) are life-threatening oppor-
tunistic infections that are an increasingly important cause
of morbidity and mortality in patients, especially those with
compromised immune function and those hospitalized with
serious underlying diseases [1, 2]. The majority of these
infections are caused by Candida spp., with over 50 %
due to Candida albicans [3–6]. Candida species are the
fourth most common pathogens isolated from patients with
nosocomial bloodstream infections in the United States and
the sixth in Europe [7–9]. These fungi are responsible for
various forms of disease, ranging from superficial infections
of the mucosal surfaces or skin to systemic infections, which
in most cases are life threatening [10]. The incidence of
candidemia in the US and Europe varies between 1.9 and
11 per 100,000 inhabitants [11–13]. Mortality in patients
with candidemia is high, ranging from 40 % to 60 %, with
reported attributable mortality of 20–40 % [9]. In general,
for treatment of an infection with Candida species, ampho-
tericin B and azole drugs are used, but these agents are not
considered to satisfy medical needs because of their toxicity,
side effects, drug interactions, limited routes, and the emer-
gence of drug-resistant and drug-low-susceptible strains
[14–21]. Among these limitations, the major obstacle in
the treatment of C. albicans infections is the spread of
antifungal drug resistance, mainly in patients chronically
subjected to antimycotic therapy, i.e., those treated with
broad-spectrum antibiotics, immunosuppressive agents,
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anticancer, and anti-AIDS drugs [22, 23]. Considering all
these factors, the identification of new antifungal small
molecules is an important goal of current anti-infective
research.
Recently, as a part of our efforts to develop new effective
antibacterial agents in the class of thiosemicarbazide deriv-
atives, a series of 4-arylthiosemicarbazides was synthesized
and their biological potency evaluated [24]. In vitro antibac-
terial activity assays indicated that compounds with
electron-withdrawing substituents in the para position are
more effective. Furthermore, it was documented for the first
time that thiosemicarbazide derivatives participate in at least
two different mechanisms of antibacterial activity. One of
these was identified as inhibition of topoisomerase IV, while
the nature of the other could not be elucidated from the
limited data collected. The binding mode of the synthesized
compounds was explored by flexible molecular docking,
which indicated the importance of H-bonding and electro-
static interactions between the thiosemicarbazide core and
amino acid residues of the ATP binding site. To further
explore the diverse biological activity of thiosemicarbazide
derivatives, we focused our attention on the antifungal ac-
tivity and structure-activity relationships (SAR) of the 4-
arylthiosemicarbazides, those already described [24–27] and
nine new derivatives, using yeast Candida as the experi-
mental model. Since selective toxicity is fundamental to the
development of anti-infective agents, cytotoxicity studies
were also carried out. Although the antifungal potential of
thiosemicarbazide derivatives is well-recognized [28–37],
thus far no detailed studies have been conducted to deter-
mine the mechanism of action and the target proteins for their
antifungal activity. As most of the existing fungal drugs are
enzyme inhibitors, the second aim of the present studies was
to identify the interactions of 4-arylthiosemicarbazides with
antifungal drug target enzymes using in silicomolecular dock-
ing. In these studies, six common and novel enzymes that
were considered in antifungal studies reported in literature
[38–41], were selected as targets, i.e., sterol 14α-
demethylase (CYP51), topoisomerase II (Topo II), L-gluta-
mine: D-fructose-6-phosphate amidotransferase (GlcN-6-P),
secreted aspartic proteinase (SAP), N-myristoyltransferase




All commercial reactants and solvents were purchased from
either Sigma-Aldrich (St. Louis, MO) or Lancaster (Wind-
ham, NH) with the highest purity and used without further
purification. Melting points were determined on a Fischer-
Johns block and are uncorrected. Elemental analyses were
determined by a AMZ-CHX elemental analyzer (within±
0.4 % of theoretical values). IR spectra were recorded in
KBr using a Specord IR-75 spectrophotometer. 1H NMR
spectra were recorded on a Bruker Avance (300 MHz).
Analytical thin layer chromatography (TLC) was performed
on Merck 60F254 silica gel plates and visualized by UV
irradiation (254 nm).
Procedure for synthesis of 4-arylthiosemicarbazides
A reaction mixture of appropriate heterocarboxylic hydra-
zide (0.01 mol) and related isothiocyanate (0.01 mol) was
heated in an oil bath at 80 °C and the progress of the
reaction was monitored by TLC. After 12 h, the reaction
was completed and crude reaction mixture was washed with
diethyl ether and crystallized from ethanol.
Physicochemical characterization of 1a-1 m, 3d, 3n, 4b,
4d, 4p, 4q, 5c, 5h, 5i, 5m, 5n, and 6b were presented
previously [24–27]. Compounds 2c, 2h, 2m, 2n are com-
mercially available.
Procedure for synthesis of s-triazole 6o-t
The thiosemicarbazide derivative 6o (0.01 mol) was dissolved
in 2 % NaOH (10 mL) and refluxed for 2 h. After cooling, the
solution was neutralized with 3M HCl. The solid formed was
filtered, dried and crystallized from ethanol.
Yields and spectral characterization of new compounds
are provided in Supplementary Material.
Antifungal assay
The primary screen was carried out by the disc-diffusion
method using agar medium, according to the Clinical and
Laboratory Standards Institute guidelines [42]. For com-
pounds showing an inhibitory effect on the growth of the
tested microorganisms—monitored as an appearance of
growth inhibition zones (GIZs)—minimal inhibitory con-
centrations (MICs) were determined using the agar dilution
method, according to Clinical and Laboratory Standards
Institute guidelines [43]. The detailed procedure was de-
scribed in a previous paper [31].
Cytotoxicity assay
Cell culture
Cell line L929 (ATTC® Catalog No. CCL-1, mouse fibro-
blasts; http://www.atcc.org) were routinely cultured in
Iscove’s modified Dulbecco medium (IMDM, Cytogen,
Princeton, NJ), supplemented with 10 % (v/v) fetal bovine
serum (FBS, Sigma), plus 2 mM L-glutamine (Sigma), 100.0
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U/ml penicillin (Sigma), 100.0 μg/ml streptomycin (Sigma),
5x10−5 M 2-mercaptoethanol (Sigma) and grown at 37 °C in
a 10 % CO2 humidified environment.
Suspensions of the compounds 1f, 1h, 1m, 2h, 5h, 6b and
6o were freshly prepared before the cells were exposed, and
diluted to appropriate concentrations; 1–1,250 μg/mL for 1f,
1h, 1m, 1–500 μg/mL for 2h, 5h, 6o, and 1–300 μg/mL for
6b with the culture medium (containing 2.5 % DMSO).
Cells treated with 2.5 % DMSO-solvent served as a control
in each experiment.
Cell viability assays
The effects of tested compounds on the viability of mouse
fibroblasts L929 cells were evaluated using the MTT [3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide] assay. The MTT assay was used according to inter-
national standards: ISO 10993-5:2009 (Tests for in vitro
cytotoxicity; http://www.iso.org/iso/catalogue_detail.htm?
csnumber036406 ). L929 cells were plated into 96-well
plates at a density of 1.0 x 104/100 μl/well in culture
medium and allowed to attach for 24 h before treatment.
Afterwards, culture medium in the plates was replaced by
100 μl compounds suspension at concentration of 0–
565 μg/ml and the cells were exposed for 24 h. Then
1 mg/ml MTT (50 μl/well) was added to each well and
incubated at 37 °C, 10 % CO2 for 2 h. Mitochondrial
dehydrogenases of viable cells reduce the yellowish water-
soluble MTT to water-insoluble formazan crystals, which
were solubilized with dimethyl sulfoxide (DMSO). The cell
culture medium was aspirated cautiously, after which 150 μl
DMSOwas added to each well and mixed thoroughly. Optical
density (OD) was read on the ELISA reader (Multiskan EX,
Labsystems; http://www.mtxlsi.com/multiskan_EX.htm) at
550 nm. The results were expressed as percentage viability
compared with the treated 2.5 % DMSO controls. All experi-
ments were performed in triplicate.
Computational details
Physicochemical parameters, HOMO/LUMO maps, and con-
formational searches were calculated using HyperChem8.0.3
[44]. Extensive conformational searches were carried out us-
ing the molecular mechanics level with the OPLS [45, 46]
force field. The most stable structures obtained were subse-
quently optimized to the closest local minimum at the semi-
empirical level using RM1 parametrization [47]. Convergence
criteria were set to 0.1 and 0.01 kcal mol−1 Å−1 for OPLS and
RM1 calculations, respectively. Electrostatic potentials were
calculated for the geometries that resulted from docking using
Gaussian 03 [48] and GaussView 5 [49] at the HF/6-31G level
[50, 51].
Automated docking setup
Flexible ligand–receptor docking was performed using the
AutodockVina program [52] using the default settings.
Models of the sterol 14α-demethylase (CYP51), topoiso-
merase II (topo II), L-glutamine: D-fructose-6-phosphate
amidotransferase (GlcN-6-P), secreted aspartic proteinase
(SAP), N-myristoyltransferase (NMT), and UDP-N-
acetylmuramoyl- L-alanine: D-glutamate ligase (MurD) bind-
ing sites based on the structure deposited in the Protein Data
Bank [53] under the PDB ID 2CIB [54], 1Q1D [55], 1XFF
[56], 1EAG [57], 1IYL [58], 1UAG [59] were employed.
Default docking parameters and flexible space of
24 x 24 x 24 Å3 were validated by re-docking native ligand
that docked exactly in the position present in the crystal
structure. Subsequently, all 4-arylthiosemicarbazides were
docked using same docking parameters.
Results and discussion
Chemistry
Six series (1–6) of 4-arylthiosemicarbazides were prepared
in high yields according to a known procedure [24–27,
60–63] in the reaction of related heterocarboxylic acid hy-
drazide with aryl isothiocyanate (Scheme 1). This one-step
reaction produced nine new (2i, 3h, 3m, 3q, 4k, 6k, 6n, 6o,
6p) and 30 known thiosemicarbazides derivatives (1a-1m,
2c, 2h, 2m, 2n, 3c, 3d, 3n, 4b, 4d, 4p, 4q, 5c, 5h, 5i, 5m, 5n,
6b).
Scheme 1 Preparation of targeted 4-arylthiosemicarbazides, series 1–6. Series 1: 1a–m; series 2: 2c, 2h, 2i, 2m, 2n; series 3: 3c, 3d, 3h, 3m, 3n, 3q;
series 4: 4b, 4d, 4k, 4p, 4q;series 5: 5c, 5h, 5i, 5m, 5n; series 6: 6b, 6k, 6n, 6o, 6p. For symbols used to identify studied compounds see Table 1
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Table 1 Symbols used to identify studied compounds using substituents at thiosemicarbazide moiety
4162 J Mol Model (2012) 18:4159–4170
In vitro antifungal activity
The in vitro antifungal activity of the title 4-arylthiosemicarbazides
(series 1–6) was tested in comparison with fluconazole against
three strains of yeast—C. albicans ATCC 10231, C. albicans
ATCC 90028 and C. parapsilosis ATCC 22019—using the
agar dilution method as described in CLSI documents M7–A7
[43]. Minimal inhibitory concentrations (MICs) were defined
as the lowest concentration of the compound preventing
growth of the tested microorganism and are listed in Table 2.
The results indicated that within series 1, compounds 1c with
the para-nitro substitution, and 1f with the ortho and para
positions substituted with chlorine atoms were the most po-
tent, exhibiting moderate activity of 50 μg/mL towards C.
parapsilosis. These compounds were also effective against C.
albicans, however at much higher concentrations (MIC range
100–200 μg/mL). Two other derivatives; 1h with para-fluoro
substitution and 1m with ortho-bromo substitution showed
somewhat lower activity, whereas remaining compounds with
halo substitution at the ortho and/or para position, 2,4-difluoro
derivative 1i, para-bromo derivative 1k, and para-chloro de-
rivative 1l, were inactive. When the thiadiazole scaffold was
replaced with the similarly sized thiophene, pyrrole or furane
(series 2, 3 and 4, respectively) antifungal potency was lost
completely except at 2h. Subsequently, the antifungal potency
of series 5 with an indole scaffold was studied. This search led
to the identification of para-fluoro derivative 5h and 2,4-
difluoro derivative 5i with MIC at 100 μg/mL towards C.
parapsilosis and marginal activity towards C. albicans.
Remaining derivatives with ortho-fluoro 5n, para-nitro 5c,
and ortho-bromo 5m substitution were inactive. Replacement
of the indole scaffold with the similarly sized isoquinoline
resulted in ortho-methoxy derivative 6o with MIC at 25 μg/
mL towards C. albicans and 50 μg/mL towards C. para-
psilosis. An antifungal response was also observed for ortho-
methyl derivative 6b, however, at somewhat higher concen-
tration; MICs at 50 μg/mL towards all screened Candida
species. Interestingly, derivatives with electron-withdrawing
substitution, para-bromo derivative 6k, ortho-fluoro derivative
6n, and para-iodo derivative 6p were inactive. Finally, the
biological activity of s-triazole 6o-t, a cyclic derivative of
the most potent 6o, was tested. No antifungal potency was
noted.
Cytotoxicity of selected compounds against L929 cells
Compounds 1f, 1h, 1m, 2h, 5h, 6b, and 6o, all of which
showed in vitro antifungal activity, were further examined
for their initial in vitro toxicity effects against mammalian
L929 cells by MTT assay. Toxicity was defined as the high-
est dilution of test samples that causes 30 % or greater
destruction of cells. Morphology of normal cells and cul-
tured cells with tested compounds are given in Fig. S1 in
Supplementary Material.
From a pharmacological point of view it is important for
the studied compounds to exhibit high bioactivity and at the
same time show no or low toxicity effects, otherwise the
activity might just be due to general toxicity, which dis-
qualifies the compound as a drug or lead molecule candi-
date. From a comparison of the results of toxicity collected
in Fig. 1 and antifungal activity tests, it can be seen clearly
that the potent anti-Candida agent 6b displays antifungal
activity at non-cytotoxic concentrations in mammalian cells.
Also, compounds 1f, 1h, and 2h were found to be non-toxic
up to 50 and 100 μg/mL, respectively, which equals the
MIC values against C. parapsilosis. Another important re-
sult from the toxicity studies is that the toxicity of the tested
compounds does not seem to be correlated to their antifun-
gal activity. For example, 1f, which was found to be non-
toxic up to the same concentration as 6b (50 μg/mL) is four-
time less active against Candida strains (MIC of 200 vs
50 μg/mL). Compound 1h, which was non-toxic up to
100 μg/mL, is only marginally active (MIC 400 μg/mL or
higher against Candida strains). In contrast, compound 5h,
Table 2 In vitro antifungal activity [minimal inhibitory concentration







1c 100 200 50
1f 200 200 50
1 h >400 400 100
1 m 400 200 100
2 h 400 200 50
5 h >400 >400 100
5i >400 400 100
6b 50 50 50
6o 25 25 50
fluconazole 1 1 2 Fig. 1 Concentration-dependent cytotoxic activity of 1f, 1h, 1m, 2h,
5h, 6b, and 6o
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which is even less antifungal than 1h was found to be non-
toxic up to 10 μg/mL, while the most cytotoxic 6o (5 μg/mL)
is the most potent antifungal. This indicates either that
these compounds may act via different mechanisms in
their antifungal activity against C. albicans and toxicity
against mammalian cells or that minor structural changes
afford important alterations in fungal cell permeability/trans-
port, etc. [64]
Molecular modeling studies
Since the in vitro antifungal activity could not be explained
reasonably in the light of theories of the influence of sub-
stituents on biological response, the difference in bioactivity
of 4-arylthiosemicarbazides was therefore investigated fur-
ther by a molecular modeling approach and docking studies
with the hope of finding a possible explanation for the
observations described above, and to provide a better un-
derstanding of the relationship between structure and anti-
fungal activity. Initially, some structural and electronic
descriptors of the title compounds were investigated (see
Table S1 in the Supplementary Material). In the structure of
4-arylthiosemicarbazide, the presence of the isoquinoline
ring and electron-donating methyl or methoxy groups (com-
pounds 6b and 6o) seemed to confer higher antifungal
potency than that of other substituted groups. They also
are characterized by favorable EB (binding energy) values
and high μ (dipole moment) and EHOMO (the highest occu-
pied molecular orbital energy) values in contrast to all other
studied compounds. Antifungal activity is probably affected
by these electronic descriptors, which can be important
parameters for the interaction of 4-arylthiosemicarbazides
with the active sites. It is known that the energies of HOMO
and lowest unoccupied molecular orbital (LUMO) orbitals
serve as indices for the electron-donating and electron-
acceptor abilities of the molecule, respectively. The higher
the energy of the HOMO, the better its electron-donating
ability. In the case of LUMO, good electron-acceptor ability
is associated with low-energy molecular orbitals. In our
results, antifungal potency is related to HOMO, which sug-
gests that electron-donor ability of the molecule is important
in determining activity. According to the frontier orbital
maps presented in Fig. 2 for representative model compound
6o, the HOMOs of each compound were localized mainly
on the sulfur atom of the thiosemicarbazide core. These
observations emphasize the possible role of the sulfur atom
in the charge transfer processes that occur when a ligand
interacts with the biological target.
Subsequently, the localization of LUMO orbitals for each
structure was analyzed. There was no quantitative correla-
tion between antifungal activity and LUMO localization, but
a trend clearly emerged; 4-arylthiosemicarbazides from se-
ries 1, 2, 5, and 6 have their LUMO situated on the hetero-
cyclic ring, whereas LUMO density for compounds from
completely inactive series 3 and 4 was distributed outside
the heterocyclic moiety, mainly on the sulfur atom. This
behavior might be interpreted in the sense that 4-
arylthiosemicarbazides with the electron-accepting character
of the heterocyclic ring at N1 position interact better with
the biological target.
Finally, conformational analysis of the studied com-
pounds was performed according to the protocol described
for 4-arylthiosemicarbazides with thiadiazole (series 1) and
indole (series 5) moieties [24]. As expected based on our
previous studies, no structural requirements needed for an-
tifungal activity of 4-arylthiosemicarbazides could be de-
duced; both isoquinoline derivatives with significant
activity, 6b and 6o, as well as inactive ones 6k, 6n, and 6p
shared very similar geometry. Again, comparison of the
molecular shape of active thiophene derivative 2h with
the most potent antifungal 6o or inactive ones 2m, 2n,
3h, 3d, 4b did not show any recognizable relationship
with activity (data not shown). Thus, the present study
manifested the importance of electronic properties rather
than the restricted stereochemistry of the molecule for
the antifungal response.
Fig. 2 Highest occupied
molecular orbital (HOMO; left)
and lowest unoccupied
molecular orbital (LUMO;
right) contour plots for
representative model compound
6o. HOMO and LUMO maps
for representative model
compounds series 1 and 5 are
presented in our previous paper
[24]
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Docking studies
As noted in the Introduction, with the hope if identifying the
fungal cellular targets of thiosemicarbazide class com-
pounds, we analyzed interactions of active and inactive
molecules with the active sites of common and novel
enzymes that were considered in antifungal studies reported
in the literature [38–41]. The following enzymes were in-
cluded in the studies: sterol 14α-demethylase (CYP51),
topoisomerase II (Topo II), L-glutamine: D-fructose-6-phos-
phate amidotransferase (GlcN-6-P), secreted aspartic protein-
ase (SAP), N-myristoyltransferase (NMT), and UDP-N-
acetylmuramoyl- L-alanine: D-glutamate ligase (MurD). The
docking simulations were performed using the program Auto-
Dock Vina, which was applied successfully in our pre-
vious studies of the binding mode of thiosemicarbazide
derivatives in the active site of bacterial topoisomerase
II [24]. The best poses of the studied compounds within
the active sites of target enzymes are displayed in Fig. 3
and their corresponding binding Gibbs free energies
ΔGb are shown in Table 3.
As indicated by the positive value of the Gibbs free
energy, none of the ligands bound the active sites of
GlcN-6-P and MurD, while potential inhibitory activities
of the studied compounds against CYP51, Topo II, SAP,
and NMT were observed. Almost all best poses in the
series 1–6 were located in a position very similar to that
of the inhibitors on which these enzymes were crystal-
lized. Some SAR trends were observed when the dock-
ing conformations and binding free energies of the
studied compounds in the active site of NMT were
analyzed. The nonpeptidic inhibitor that NMT was crys-
tallized with contains a benzofuran core and a long
aminoaliphatic chain. From among the compounds stud-
ied by us, those containing an isoquinoline ring (series
6) show more favorable binding affinity than the native
ligand, and bind to the site occupied by the benzofuran
ring. The remaining compounds, series 1–5, show bind-
ing Gibbs free energies lower than the native ligand,
and bind to the site occupied by the aminoaliphatic
chain situated at position 4 of the benzofuran ring,
except for 1a, 1b, 2h, 5c, 5h, 5i, and 5m (Fig. 4). This
supports the conclusion reached from experiments [58] that
the part of the active site to which the benzofuran
moiety is allocated is responsible mainly for binding.
Another significant finding is that, with the exception of
CYP51 (ID 2cib)
Topo II (ID 1q1d)
SAP (ID 1eag)
NMT (ID 1iyl) 
Fig. 3 Superimposition of the native ligand (rendered as tubes) and the
best conformations of representative ligands 1a, 1b, 1c, 1f, 1 h, 1 m, 2c,
2 h, 3n, 3q, 4d, 4 k, 5c, 5 h, 5i, 5n, 6b, 6n, 6o, and 6p docked to the
binding site of sterol 14α-demethylase (CYP51) (ID 2cib), topoiso-
merase II (Topo II) (ID 1q1d), secreted aspartic proteinase (SAP) (ID
1eag), and N-myristoyltransferase (NMT) (ID 1iyl)
J Mol Model (2012) 18:4159–4170 4165
2h and 2i, all compounds bind to the active site of
NMT without H-bond interactions with amino acid residues.
This is a very important result, which points to the fact that the
electronic nature of a molecule may play the key role in ligand
recognition.
Subsequently, we focused on isoquinoline derivatives
(series 6) as this series contains the two most active
compounds: 6b and 6o. Based on the conformations
obtained from docking studies, we generated electrostat-
ic potential surfaces. As seen in Fig. 5, the most active
compound (6o) is characterized by electrostatics around
the sulfur atom that differ significantly from that in the
other ligands. The is explained mainly by the opposite
orientation of the proton in the neighboring NH group.
Following this finding, we analyzed the geometry of
this fragment of the thiosemicarbazide skeleton in detail
(Table 4). The opposite location of the NH proton is
characterized by the HN(N)CS dihedral angle being
significantly different, and opposite in sign to that in
all other compounds. The graphical representation of the
different electrostatics in this part of 6o presented in
Fig. 5 was quantified by the Mulliken partial atomic
charge at the sulfur atom, which was also significantly
different and opposite in sign than in other ligands. Two
other geometric parameters, i.e., C–S bond distance and
HN(C)CS dihedral angle, are also distinct in the case of
6o. It should be noted that these differences are very
subtle and can be easily overlooked. The importance of
electrostatics and geometry of the –NH–C(0S)–NH–
fragment can be further inferred from the corresponding
parameters of the methyl derivative 6b. As can be seen
in Table 4, 6b is closer to 6o than to the remaining
ligands. This correlates well with bioactivity, with that
of 6b being lower than that of 6o and the other ligands
being inactive.
Based on the above analysis, we also addressed the
question of the lack of antifungal activity of s-triazole
6o-t, which is a dehydroderivative of the most active
thiosemicarbazide 6o. We docked compound 6o-t to the
active site of NMT. As illustrated in Fig. 6, the best
pose of 6o-t shows only partial overlap with the
corresponding pose of 6o, which coincides well with
the position of the ligand used in crystallographic stud-
ies. Most importantly, the orientation of the N–C(0S)–N
fragment of the s-triazole ring is completely different
and the location of the sulfur atom within the active site
is completely different, 8.7 Å away from the location of
sulfur atom of 6o, which, as argued above, influences
the antifungal activity of this ligand. Thus, the structural
and electronic factors of the NH-NH–C(0S)–NH core
seem to be important for ligand recognition and, conse-
quently, for the antifungal effectiveness of the studied 4-
arylthiosemicarbazides. Only use of specific enzymatic
bioassays, will allow this hypothesis to be confirmed
and the biological target of the tiosemicarbazide class of
compounds to be identified unequivocally.
Table 3 Binding free energy (ΔGb) corresponding to the best docking
poses of compounds from series 1–6 in the active site of CYP51 (ID
2cib), Topo II (ID 1q1d), GlcN-6-P (ID 1xff), SAP (ID 1eag), NMT
(ID 1iyl), and MurD (ID1uag)
Compound ΔGb (kcal/mol)
CYP51 Topo II GlcN-6-P SAP NMT MurD
Ligand -11.5 -11.8 -7.9 -8.0 -9.1 -5.1
1a -6.8 -8.4 2.9 -7.1 -7.4 19.2
1b -7.1 -8.4 5.0 -7.0 -8.1 22.8
1c -7.1 -8.6 4.6 -7.0 -7.6 22.8
1d -7.0 -8.4 5.2 -7.1 -7.1 20.8
1e -7.5 -8.9 7.3 -7.4 -8.4 24.8
1f -7.1 -8.9 7.8 -7.4 -7.6 24.9
1 g -6.9 -8.6 3.3 -7.2 -7.6 19.9
1 h -7.0 -8.2 3.4 -7.2 -7.8 19.4
1i -7.3 -8.9 4.9 -7.7 -7.8 20.8
1j -7.2 -8.8 4.8 -7.8 -7.7 21.6
1 k -7.1 -8.5 7.8 -6.9 -7.2 21.7
1 l -7.1 -8.5 5.3 -7.3 -7.3 21.2
1 m -7.2 -8.3 5.9 -6.7 -7.6 23.6
2c -7.1 -8.2 7.1 -6.8 -7.6 20.8
2 h -7.5 -7.7 2.5 -6.7 -7.6 19.2
2i -7.4 -7.9 2.1 -7.4 -7.8 19.1
2 m -7.1 -7.7 3.8 -6.6 -7.4 21.2
2n -7.2 -7.7 1.8 -7.2 -7.7 18.6
3c -7.3 -8.7 2.4 -6.5 -7.7 18.6
3d -7.5 -8.0 2.6 -6.6 -7.5 17.6
3 h -7.7 -8.1 1.7 -7.3 -7.6 14.8
3 m -7.4 -7.9 2.6 -6.3 -7.8 18.4
3n -7.0 -8.1 0.9 -7.5 -7.9 15.6
3q -7.8 -8.1 1.8 -6.9 -7.7 16.4
4b -7.5 -8.0 4.9 -7.4 -8.1 20.6
4d -7.1 -7.8 5.7 -7.0 -7.4 21.1
4 k -7.3 -7.8 7.0 -7.0 -7.4 22.1
4p -7.2 -7.9 8.0 -7.0 -7.4 24.5
4q -7.5 -8.0 3.6 -7.3 -7.5 19.5
5c -9.7 -10.0 12.2 -7.2 -8.2 34.1
5 h -9.4 -8.4 10.6 -7.5 -8.2 28.4
5i -9.6 -8.7 11.6 -7.8 -8.7 30.9
5 m -9.5 -9.1 10.6 -8.8 -8.1 32.5
5n -9.4 -8.6 8.0 -7.5 -7.7 29.1
6b -7.9 -8.8 11.9 -7.0 -10.1 33.6
6 k -8.2 -9.1 17.2 -7.0 -10.1 37.9
6n -7.9 -8.9 11.7 -7.4 -9.8 31.2
6o -7.7 -9.0 18.5 -6.9 -9.5 34.6
6p -8.2 -8.9 19.3 -7.0 -10.0 40.6
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Conclusions
The present study evaluated the in vitro antifungal activities of
six series of 4-arylthiosemicarbazides. Among the compounds
tested, two isoquinoline derivatives 6o and 6b were the most
potent antifungals. Subsequently, molecular modeling and flex-
ible docking studies were carried out to identify and characterize
the structural and electronic properties that modulate the
antifungal potency of 4-arylthiosemicarbazides. The electronic
requirements for antifungal effectiveness deduced from the mo-
lecular modeling approach are (1) high HOMO and dipole
moment values, (2) favorable binding energy, and (3) the pres-
ence of an electron accepting heteroaromatic ring at N1 position
of thiosemicarbazide skeleton. The structural and electronic
requirements for ligand recognition deduced from comparisons
of ligands in the active site of NMTare (1) high-electron density
series 1 series2
series 3 series 4
series 5 series 6
Fig. 4 Superimposition of the
native ligand (rendered as
tubes) and the best
conformations of ligands from
series 1–6 docked to the
binding site of NMT (1iyl)
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around the sulfur atom, and (2) geometry of NH-NH-C(0S)-NH
core. The results of the docking study of inactive s-triazoles 6o-t,
a dehydroderivative of the most potent antifungal agent 6o,
confirmed the validity of the pharmacophore model developed
for 4-arylthiosemicarbazides, although additional experimental
evidence is needed to support this hypothesis. Efforts aimed at
elucidating the antifungal mechanism of action of 4-
arylthiosemicarbazides using biochemical approaches are under-




Fig. 5 Comparison of the electrostatic potential surfaces of compounds from series 6 that resulted from docking studies at the active site of NMT
Table 4 Sulfur charge density (|e−|), selected bond lengths (Å) and
torsional angles (°) of compounds from series 6
Compound S charge density C0S HN(C)CS HN(N)CS
6b 0.012 1.610 -58.8 -71.0
6 k 0.064 1.608 -79.6 -58.9
6n 0.074 1.608 -87.1 -56.1
6o -0.016 1.612 -99.8 171.6
6p 0.070 1.609 -82.1 -60.9 Fig. 6 Superimposition of the best conformations of 6o and 6o-t
docked to the binding site of NMT (1iyl)
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